State of Wisconsin Investment Board raised its stake in Allergan PLC. (NYSE:AGN) by 14.1% during the first quarter, Holdings Channel reports. The institutional investor owned 391,609 shares of the company’s stock after buying an additional 48,248 shares during the period. State of Wisconsin Investment Board’s holdings in Allergan PLC. were worth $93,563,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in AGN. Crestwood Advisors Group LLC acquired a new position in Allergan PLC. during the first quarter valued at about $103,000. Sunbelt Securities Inc. acquired a new position in Allergan PLC. during the fourth quarter valued at about $107,000. Feltz Wealth PLAN Inc. acquired a new position in Allergan PLC. during the first quarter valued at about $107,000. Enterprise Financial Services Corp boosted its position in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares in the last quarter. Finally, Webster Bank N. A. boosted its position in Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock valued at $124,000 after buying an additional 123 shares in the last quarter. 84.88% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Shares of Allergan PLC. (NYSE AGN) opened at 235.49 on Friday. The firm’s 50-day moving average price is $230.75 and its 200 day moving average price is $226.62. The stock has a market capitalization of $79.09 billion, a P/E ratio of 7.34 and a beta of 1.16. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $261.27.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings results on Tuesday, May 9th. The company reported $3.35 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.32 by $0.03. The company had revenue of $3.57 billion for the quarter, compared to analysts’ expectations of $3.53 billion. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.04 earnings per share. Analysts expect that Allergan PLC. will post $16.08 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 15th. Stockholders of record on Thursday, May 18th were issued a dividend of $0.70 per share. The ex-dividend date of this dividend was Tuesday, May 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.19%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.63%.

WARNING: This piece of content was originally reported by Financial Market News and is the sole property of of Financial Market News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.financial-market-news.com/2017/06/17/state-of-wisconsin-investment-board-has-93-56-million-stake-in-allergan-plc-agn.html.

Several research analysts have recently issued reports on AGN shares. Mizuho lowered their price objective on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a research report on Friday, June 9th. Cowen and Company set a $400.00 price objective on Allergan PLC. and gave the stock a “buy” rating in a research report on Thursday, June 8th. Royal Bank Of Canada set a $279.00 price objective on Allergan PLC. and gave the stock a “buy” rating in a research report on Wednesday, April 12th. Deutsche Bank AG upped their price objective on Allergan PLC. from $262.00 to $265.00 and gave the stock a “buy” rating in a research report on Tuesday, March 28th. Finally, Vetr raised Allergan PLC. from a “hold” rating to a “buy” rating and set a $256.33 price objective for the company in a research report on Wednesday, March 1st. Seven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $272.13.

In other news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.36% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.